Evoke PharmaEVOK
13F holders, Q2 2025 (June 30)10holders
1new positions
1sold out
1famous investor
$2.60avg. 13F price*
At the end of Q2 2025, 10 institutions reported holding Evoke Pharma Inc. (EVOK) in their 13F filings, unchanged from Q1 2025. 1 opened new positions and 1 sold out. The largest holders were Nantahala Capital Management, LLC ($385K), Bleichroeder LP ($179K) and Citadel Advisors ($33K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Evoke Pharma Inc.
- CUSIP
- 30049G302
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $792 |
| Exits | 1 | $12K |
All 13F filers, Q1 2025 → Q2 2025: 2,077 shares bought and 32,261 shares sold, net −30,184 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Nantahala Capital Management, LLC | 0.03% | No change | 148,153 | $385K |
| Bleichroeder LP | 0.04% | No change | 68,750 | $179K |
| Citadel Advisors | 0.00% | Reduce -49.4% | 12,542 | $33K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +833.3% | 1,988 | $5K |
| FMR LLC | 0.00% | New | 301 | $792 |
| BlackRock, Inc. | 0.00% | No change | 122 | $317 |
| SBI Securities Co., Ltd. | 0.00% | No change | 75 | $195 |
| Morgan Stanley | 0.00% | No change | 64 | $166 |
| NewEdge Advisors, LLC | 0.00% | No change | 17 | $44 |
| Bank of America Corp. | 0.00% | Add +11.1% | 10 | $26 |
"% of holder's portfolio" is EVOK's weight in each manager's 13F, not the share of Evoke Pharma Inc. the manager owns.